B
Bull
Bull · 25%PTHL
$24.92
情境價格
$0.902
+0.949 (+105.16%)收盤時
Loading chart…
- High
- 1.090
- Open
- 0.423
- VWAP
- 0.79
- Vol
- 74.89M
- Mkt Cap
- —
- Low
- 0.391
- Amount
- 59.49M
- EV/EBITDA, TTM
- 0.00
iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.
估值指標
The current forward P/E ratio for Pheton Holdings Ltd (PTHL) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for PTHL
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
2.008-14PRnewswireiTonic Holdings Faces Class Action Over Market Manipulation Allegations
7.008-11PRnewswirePheton Holdings Securities Class Action Reminder
7.008-07PRnewswireiTonic Holdings Sued for Market Manipulation Allegations
8.512-05GlobenewswirePheton Acquires 51% of iTonic, Expanding into Home Health Market
8.512-05NewsfilterPheton Acquires 51% of iTonic, Expanding into Home Health Market
PTHL FAQ — answered by Alphio AI
iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others. It operates in the Healthcare sector.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。